Pharmaceutical Stocks

Pharmaceutical stocks have grown tremendously as medicine advances. With diseases like Covid-19, diabetes, liver disease and other illnesses affecting more and more of the population, pharmaceutical companies are racing to find cures – further advancing medicine and driving pharma stock prices higher.

Big Pharma corporations like AstraZeneca, Merck & Co., Pfizer, and Johnson & Johnson are leading the charge against the novel coronavirus, competing with smaller biotech names — such as Moderna and Novavax. The race to find a Covid-19 vaccine has sent both pharma and biotech stocks to the moon.

Pfizer Tops Q2 Earnings Estimates

By Christopher Freeburn, InvestorPlace Writer
Pfizer posted second-quarter earnings that topped Wall Street estimates even as revenue declined compared to last year.

Should I Buy Merck? 3 Pros, 3 Cons

By Tom Taulli, InvestorPlace Contributor
Pharma is a tough game, but thanks to its simultaneous continued R&D spending and cost-cutting, Merck has what it takes to win. Or does it?

Before You Assume the Worst for Vivus …

By James Brumley, InvestorPlace Feature Writer
While there are many reasons to be pessimistic about the future of pharma stock Vivus, the research that has fueled its recent drop is not one of them.

5 Health Care Mutual Funds to Buy

By Kyle Woodley, Senior Investing Editor, Kiplinger
As the baby boomers get creakier, health care is sure to flourish. These funds are a good way to get into this must-have sector.

Is It Time to Sell Abbott Labs?

By James Brumley, InvestorPlace Feature Writer
Abbott Labs has been on a tear since October, but its technical strength is wearing thin, plus a few other factors stand to hamper this otherwise solid company.

Novartis Wins Approval for Breast Cancer Drug

By Christopher Freeburn, InvestorPlace Writer
The FDA has granted approval for Novartis' drug Afinitor to be used as a treatment for breast cancer after it showed promise in clinical trials.

Divided, This Rally Cannot Stand!

By Sam Collins, InvestorPlace Chief Technical Analyst
The fact that Thursday's rally was restricted to just several sectors following a breakout means a slight correction could be due. Watch for new entry points.

7 Long-Term Demographic Trends to Play

By Alyssa Oursler, InvestorPlace Contributor
Earnings and stock fundamentals are important, but don't miss the forest while looking at the trees. Here are the big-picture demographic trends to keep your eye on.

Nothing’s Slowing Down Abbott Labs

By John Kmiecik, InvestorPlace Contributor
ABT has been in a solid uptrend for some time now, and it has little overhead resistance technically. Consider this options trade to play ABT's momentum.

HGSI Holdout Proves Profitable — for Bagels

By Marc Bastow, InvestorPlace Assistant Editor
Joint pharmaceutical developers Human Genome and GlaxoSmithKline agreed to a sweetened $14.25/share offer for HGSI, cheering Rockville-area diners.

Merck Could Have a Home Run in Sight

By James Brumley, InvestorPlace Feature Writer
Merck’s new drug odanacatib can be thanked for the stock's recent rally, but there are two questions that need to be answered.

Investors Bag the Groceries: Thursday’s IP Market Recap

By Marc Bastow, InvestorPlace Assistant Editor
Markets were down as continued worries about Europe and another round of disappointing earnings and guidance pushed prices lower.

4 ETFs to Guard Against Market Volatility

By Susan J. Aluise, Aviation, Auto & Transportation Writer
Worried about the market's current uncertainty? A good defensive play right now is low-risk, low-beta ETFs. Here are four of the best.

Glaxo to Pay $3B in Fines for Improper Drug Marketing

By Christopher Freeburn, InvestorPlace Writer
GlaxoSmithKline will pay $3 billion in fines relating to its promotion of the antidepressant drugs, Paxil, Wellbutrin and Avandia, and the asthma drug Advair.

M&A: Where the Hotspots Are

By Tom Taulli, InvestorPlace Contributor
Both the number of deals and their value are down, but there's strong signs of life if you know where to look. Here's a guide to where the action is.

Should I Buy Bristol-Myers Squibb? 3 Pros, 3 Cons

By Tom Taulli, InvestorPlace Contributor
Its deal to buy diabetes-drug maker Amylin will help, given that market's potential. Still, patent expirations loom large and won't be easily overcome.

What’s the Real Impact of Generic Drugs?

By James Brumley, InvestorPlace Feature Writer
The danger of patent expirations for big pharma isn't new, but the amount of market share those brands are losing to generics as a result are not pretty.

3 Reasons to Flee Walgreen

By Susan J. Aluise, Aviation, Auto & Transportation Writer
The market is worried that Walgreen is still struggling to fill the right prescription at the right time. Here are three signs that spell trouble for WAG shares.

5 of Pharma’s Most Disastrous Drug Approvals

By James Brumley, InvestorPlace Feature Writer
These five exciting drug approvals now serve as warning stories about the potential pitfalls for investors trying to time a pharma stock buy.
Load More